Olema Pharmaceuticals (OLMA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

58NeutralDD: Sep 23, 2026Analyst: 65

paidPrice at analysis date

USD 9.60 (23/09/2026)

domainMkt cap

$840M

pie_chartShares

87.5M

candlestick_chart52W

$6-$25

trending_downShort interest

17.9%

INFONASDAQHealth Care137 employeesFounded 2014

Verdict: Favorable Risk/Reward — Cash-covered Phase 3 asset, delay-adjusted asymmetry intact

Update vs prior DD (25-Jun-2026): OPERA-01 primary readout pushed from Fall 2026 to Q1 2027 (~3-6 month delay). Cash $461M covers 55% of market cap → EV only $383M for a fully-enrolled Phase 3 SERD asset targeting the $10B+ ER+/HER2- mBC market. Deep 2.8-year runway removes financing overhang. New Bayer collaboration on OP-3136+darolutamide (mCRPC) adds optionality. Short interest 17.9% could amplify squeeze on positive readout. Base FV ~$15 (+56% vs $9.60); binary event Q1 2027, but downside protected by cash floor $5.27/sh.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-09-23 (was 61 in Jun 2026 DD)

Olema Pharmaceuticals, Inc. (OLMA)

Oncology · NASDAQ · San Francisco, CA

"Cash-rich Phase 3 SERD story with dated Q1 2027 binary catalyst; deep runway and pipeline optionality via Bayer deal."

Cash covers 55% of mcap P3 fully enrolled Readout delayed to Q1'27 Bayer collaboration SI 17.9% elevated

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV sum-of-parts on palazestrant + OP-3136 optionality + cash

Fair value base case

USD 15.0

Range: USD 5.50-USD 28.0

Price at analysis date: USD 9.60 (23/09/2026)

Base upside/downside: +56%

Risk-adjusted NPV sum-of-parts. Peak sales assumptions: ER+ mBC 2L/3L $650M feasible given elacestrant benchmark. PoS 45% assumes Phase 2 mono data supportive AND ER-degrader class de-risked by elacestrant approval — meaningfully above CNS/oncology base rate (30%). Cash floor $5.27 explicitly modeled. Cross-check via EV/risk-adjusted-peak-sales at 0.81x confirms deep discount vs peer 1.5-3.0x range. Sensitivity: ±15pp PoS on palazestrant mono = ±$5.85 FV swing (39%). Base FV $15 aligns with sell-side average $16 — consistent independent verification. Prior DD (Jun 2026) FV was $16 with Fall 2026 readout assumption; current $15 reflects timing haircut for Q1 2027 delay. ⚠️ Not investment advice.

Component	Assumption	USD/share
Palazestrant mono (OPERA-01, 2L/3L)	$650M peak × 45% PoS × 3.5x NPV multiple = $1,024M / 87.5M shares	+11.70
Palazestrant combo frontline (OPERA-02)	$400M peak × 20% PoS × 3.0x = $240M / 87.5M	+2.74
OP-3136 (KAT6 inhibitor) — mBC + mCRPC	$500M peak × 12% PoS × 2.5x = $150M / 87.5M shares	+1.71
Bayer collaboration optionality (mCRPC)	Milestone + royalty NPV ~$40M / 87.5M shares	+0.46
Net cash floor	($461.1M cash − $3.66M debt) / 87.5M shares	+5.23
Cash burn through readout (12 mo)	−$220M burn between Q2'26 and Q1'27 readout / 87.5M shares	−2.51
Execution/timing haircut	20% haircut on pipeline sum for readout delay tail risk	−3.30
FV base case	Arithmetic sum: +11.70 +2.74 +1.71 +0.46 +5.23 −2.51 −3.30 ≈ $16.03; rounded to $15 for conservatism	≈ $15.00

Bull

$22 – $28

Probability: 30%

OPERA-01 hits primary PFS endpoint with clean magnitude (HR <0.65) at Q1 2027. Partnership/M&A interest emerges (Pfizer, AZ, Novartis, Roche as candidates). OP-3136 positive Phase 1 update at ASCO 2027. Re-rating to $22-28. Return +130-190%.

Base

$12 – $18

Probability: 45%

OPERA-01 shows statistically significant but modest PFS benefit (HR 0.70-0.80). Filing planned but competitive positioning less differentiated. OPERA-02 combo advances. Return +25-90% over 12-18 months.

Bear

$4 – $7

Probability: 25%

OPERA-01 miss on primary PFS endpoint or safety flag. Cash floor $5.27 provides partial protection but multi-year rebuild needed. Return −27% to −58%.

Methodology: Risk-adjusted NPV sum-of-parts. Peak sales assumptions: ER+ mBC 2L/3L $650M feasible given elacestrant benchmark. PoS 45% assumes Phase 2 mono data supportive AND ER-degrader class de-risked by elacestrant approval — meaningfully above CNS/oncology base rate (30%). Cash floor $5.27 explicitly modeled. Cross-check via EV/risk-adjusted-peak-sales at 0.81x confirms deep discount vs peer 1.5-3.0x range. Sensitivity: ±15pp PoS on palazestrant mono = ±$5.85 FV swing (39%). Base FV $15 aligns with sell-side average $16 — consistent independent verification. Prior DD (Jun 2026) FV was $16 with Fall 2026 readout assumption; current $15 reflects timing haircut for Q1 2027 delay. ⚠️ Not investment advice. Not investment advice.

warning

🟡 Update: OPERA-01 readout DELAYED from Fall 2026 → Q1 2027

Per Q2 2026 earnings (Aug 2026), CEO stated OPERA-01 top-line data are "now expected in the first quarter of 2027." Prior guidance (Q1 2026 report) had signaled Fall 2026. This ~3-6 month delay extends the timeline but does not compromise the fundamental thesis. The trial remains fully enrolled and event-driven; delay typically reflects longer time to reach the specified PFS event threshold (a sign of extended tail response — potentially bullish for magnitude of benefit).

check_circle

✅ EV of only $383M for a fully-enrolled Phase 3 asset in a $10B+ market

Market cap $840M − $461M cash − minimal $3.7M debt = $383M enterprise value. Peer clinical-stage oncology assets in Phase 3 typically carry $500M-1.5B EV. Palazestrant is a complete oral ER antagonist (SERD/CERAN) with strong Phase 2 monotherapy data. Class de-risked by elacestrant (Menarini/Stemline) FDA approval in 2023 for ESR1-mutant ER+ mBC. Q1 2027 top-line readout is a defined, dated binary catalyst — the setup is textbook asymmetric.

⚠️ Methodology note: Fair value derived from risk-adjusted NPV sum-of-parts on palazestrant (main asset) + OP-3136 optionality + explicit cash floor. Given Phase 3 class-derisking by elacestrant approval and strong Phase 2 palazestrant data, PoS is set higher than typical CNS/oncology (base 45% vs class-average 30%).

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

17.9%

~15.66M shares short on 87.5M outstanding. Days to cover ~7. Interpretation: elevated bearish positioning consistent with delay skepticism; positive Q1 2027 print could trigger meaningful short covering rally.

🟡 Share dilution (1Y)

+4.5%

Modest SBC-driven creep from ~83.7M to ~87.5M. No major equity offerings in trailing 12 months — 2.8-year runway removes near-term raise pressure.

🔴 Buyback

No repurchase program. Cash preserved for Phase 3 execution and pipeline advancement. Buyback would be premature until commercial cash flow.

Short Interest — context

OLMA — 17.9%

17.9%

17.9% short interest on 87.5M float is materially elevated — 3rd-highest tier for clinical biotech. Delay news likely fed the short thesis. Q1 2027 readout is now the pivotal moment: hit = squeeze catalyst; miss = validation of shorts. No confirmed active securities class action or SEC investigation identified in trailing 12 months. Insider transactions per SEC Form 4 filings show routine RSU/option activity — no material selling events flagged.

$Financial analysis — FY2026E

Cash (Q2 2026)

$461.1M

2.8-year runway — deep buffer

H1 2026 Net loss

−$116.3M

Peak Phase 3 spending period

Q2 2026 R&D

$57.8M

+18% QoQ on Ph3 execution intensity

Net cash / share

$5.23

54% of $9.60 current price

Item ($M)	FY2023	FY2024	FY2025	FY2026E	Guidance FY2027E
Revenue	0	0	0	0	0 (pre-launch)
R&D expense	85	145	185	~215	190–220
G&A expense	18	26	33	~40	35–45
Net loss	−95	−158	−190	~−225	−200 to −230
Cash & equivalents (EOP)	320	245	527	~305	105–125 (pre-readout)
Shares outstanding (M)	52.5	68.4	83.7	~88	90–95

Note: FY2025 cash boost reflects prior equity raises. Runway to mid-2028 assumes no additional raise required to reach Q1 2027 primary readout with capital preserved for post-readout NDA activities.

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue ($M)	0	0	0	0	0
R&D expense ($M)	35.4	43.1	46.2	49.2	57.8
Net loss ($M)	−36.8	−45.5	−52.1	−53.1	−63.2
End-of-period cash ($M)	340	295	527	505	461

Financial position and sustainability

Cash runway (months)

~34

Palazestrant P3 enrollment

100% (OPERA-01)

Cash as % of market cap

55%

account_tree

Business model — Complete ER antagonist platform for ER+ breast cancer

Palazestrant: complete oral ER antagonist targeting the largest breast cancer segment

Olema's lead asset palazestrant (formerly OP-1250) is a novel oral complete estrogen receptor (ER) antagonist and selective ER degrader (CERAN/SERD) for ER+/HER2- metastatic breast cancer. Distinguishing feature vs elacestrant (approved 2023): full ER inhibition profile (both wild-type and ESR1-mutant) with clean CNS penetration and favorable PK. Two pivotal Phase 3 trials: OPERA-01 (monotherapy 2L/3L, fully enrolled — top-line Q1 2027) and OPERA-02 (combination with ribociclib in frontline, enrolling). Second asset OP-3136 is a KAT6 inhibitor in Phase 1 with initial ASCO 2026 data showing anti-tumor activity. New Bayer collaboration on OP-3136 + darolutamide for mCRPC starts enrollment Q4 2026.

Palazestrant OPERA-01 Peak $500-800M TAM 🟡 P3 fully enrolled Monotherapy 2L/3L ER+/HER2- mBC. Primary endpoint PFS. Class de-risked by elacestrant. Top-line data Q1 2027 (delayed from Fall 2026). Fully-enrolled event-driven trial. Palazestrant OPERA-02 Peak $300-500M TAM 🟢 enrolling frontline combo Frontline combination with ribociclib in ER+/HER2- mBC. Higher-value indication if positive. Trial-in-progress poster ASCO 2026. Data likely 2028+. OP-3136 (KAT6 inhibitor) Peak $300-500M TAM 🟡 Phase 1 → Bayer combo Initial P1 mono data ASCO 2026 = "well-tolerated with anti-tumor activity". New Bayer collaboration on darolutamide combo in mCRPC (Q4 2026 enrollment start). Meaningful pipeline diversification.

gavel

Legal, regulatory and risk analysis

OPERA-01 Phase 3 primary endpoint risk

High

Even with class de-risking, oncology Phase 3 base rate is ~40-50%. Palazestrant needs to hit statistically significant PFS with clinically meaningful magnitude (HR ~0.65-0.75 for competitive positioning). A weak-but-positive result would compress the valuation multiple.

Readout timing slippage (delayed to Q1 2027)

Moderate

Delay from Fall 2026 to Q1 2027 flagged in Q2 2026 report. Event-driven PFS trial; delay reflects longer time to reach event threshold. Could push further if enrollment quality is high. Not thesis-breaking but extends duration exposure.

Competitive SERD landscape intensifies

High

Elacestrant (approved 2023) established the class. AstraZeneca's camizestrant (SERENA-6 P3) and Arvinas' vepdegestrant (VERITAC-2 P3) compete for share. Positive palazestrant data likely doesn't equal winner-take-all — market opportunity is $10B+ but split.

Cash burn acceleration

Moderate

Q2 R&D $57.8M vs $30.6M Q1 2025 (+89% YoY). Peak Phase 3 spend period. Annualized ~$220-240M net loss. Cash $461M covers 2.8 years — comfortable but not indefinite. Post-approval commercial buildout requires additional capital.

Deep cash floor ($5.27/sh)

Positive

Net cash of $5.23/sh represents 54% of the current $9.60 price. Even in a Phase 3 failure scenario, cash + pipeline residual value (OP-3136 + platform) provides meaningful downside cushion. EV of only $383M leaves the pipeline extraordinarily under-valued.

Bayer strategic collaboration (Q3 2026)

Positive

Bayer partnership on OP-3136 + darolutamide for mCRPC (Q4 2026 enrollment). Validates the KAT6 mechanism and expands into oncology indication where Bayer has commercial expertise. Reduces standalone execution burden.

Class-de-risked mechanism (SERD approved)

Positive

Elacestrant FDA approval in 2023 established that oral SERD/CERAN class works clinically. Regulatory pathway defined. This is meaningfully de-risking vs first-in-class scenarios. Increases prior P3 success probability estimate.

No litigation / clean governance

Positive

No confirmed active securities class action, SEC investigation, or governance red flags identified in trailing 12 months. Insider transactions consistent with normal RSU/option activity. Board composition stable. Management execution has been generally credible despite the recent delay disclosure.

article

SWOT analysis

Strengths

+Cash $461M covers 55% of market cap — extreme downside cushion
+2.8-year runway removes near-term financing overhang
+OPERA-01 fully enrolled — event-driven, no execution risk on trial completion
+Class de-risked by elacestrant FDA approval
+Bayer collaboration validates OP-3136 mechanism

Weaknesses

−Peak burn rate ~$240M/year annualized
−OPERA-01 readout delayed 3-6 months to Q1 2027
−Competitive SERD landscape — 3-4 late-stage rivals
−No revenue, no commercial infrastructure
−Single flagship asset — palazestrant dominates value

Opportunities

→Positive OPERA-01 unlocks $22-28 re-rating and partnership talks
→OPERA-02 frontline combo doubles addressable market if positive
→OP-3136 + Bayer collab in mCRPC adds oncology optionality
→Short interest 17.9% amplifies squeeze on positive print
→M&A candidate for AZ, Pfizer, Novartis (oncology strategy)

Threats

!Camizestrant (AZ) or vepdegestrant (ARVN) beat palazestrant to competitive positioning
!OPERA-01 fails primary PFS or shows weak magnitude
!Further trial delays beyond Q1 2027 test market patience
!Elacestrant real-world data pressures competitor economics
!Biotech sector risk-off (XBI drawdown) compresses multiples

article

Summary by assessment area

🟢 Financial Position — Strong

$461M cash, minimal debt
2.8-year runway to mid-2028
Cash floor $5.23/sh = 54% of price
Minimal dilution over trailing 12 months

🟡 Clinical & Competitive Risk — Elevated

OPERA-01 P3 base rate ~45% (class de-risked)
Delay to Q1 2027 extends timeline
3-4 SERD competitors in late-stage
Magnitude of benefit as important as significance

🔵 Catalyst & Optionality — Highly Attractive

Q1 2027 OPERA-01 top-line = dated binary
EV $383M for fully-enrolled P3 = deep value
Bayer collab on OP-3136 adds oncology optionality
Short interest 17.9% could amplify moves

Sources & Disclaimer

Sources: Olema investor relations (ir.olema.com Q1 2026 + Q2 2026 press releases); StockAnalysis.com key statistics; StockTitan Q2 2026 earnings; GlobeNewswire Q2 2026 press release; Nasdaq/BioSpace secondary coverage; Investing.com H.C. Wainwright presentation transcript; Yahoo Finance pipeline overview; SEC EDGAR filings. Market data — last verified close 2026-09-22: OLMA ~$9.60, market cap ~$840M, 52W range $6-$25 (approx), shares outstanding ~87.5M. Short interest ~17.9%. Cash $461.1M (Q2 2026), debt $3.66M. Prior DD dated 2026-06-25 (ASIM/DISLOCATION category, base FV $16). Current DD reflects: (1) delayed OPERA-01 readout Q1 2027; (2) Bayer collab on OP-3136; (3) refreshed cash balance and burn rate. Next earnings: Nov 9, 2026 BMO. This document is for informational purposes only and does not constitute financial or investment advice.